Oncology
🇺🇸 FDAFDA news and analysis for pharmaceutical BD, investment, and market access
Global oncology market intelligence for pharma BD, investors, and analysts. Track drug approvals, clinical trials, and competitive landscapes.
Showing 1–12 of 246 articles
Quick answer
NovaPharmaNews Oncology hub for FDA covers 246 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
FDA approves Vepdegestrant (Veppanu) for ESR1-mutated breast cancer
SLS Stock Jumps on Biotech Momentum as SELLAS Gains 25.10%
Cardiff Oncology pipeline update: onvansertib trials, FDA meeting, and catalysts
Tillomed Laboratories update: pipeline, melphalan and next catalysts
Breast Cancer Statistics Worldwide: What the Data Shows
Merck’s Harpoon acquisition deepens oncology pipeline ahead of Keytruda risk
Johnson And Johnson ASCO 2026 Data Adds Depth To JNJ Valuation Story
Celcuity Expands VIKTORIA-2 Trial as Shares Trade Below Analyst Targets
May 2026 FDA Oncology Actions: 8 Approvals Reshape the Landscape
Tip Sheet GLP-1s and Cancer: Key Insights for Pharma BD and Investors
Kairos Pharma Highlights CL-741 Acquisition and 2026 Clinical Milestones: A Strategic Analysis for Pharma Decision-Makers
FDA Approves Companion Diagnostic for Inavolisib in HR+/HER2–, PIK3CA-Mutated Breast Cancer
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.